University sells Aids drug rights for $525m
Emory University has sold the royalty rights for an Aids drug it developed for $525 million (£300 million), marking one of the biggest payments to a US university for intellectual property. The Atlanta institution decided to accept a one-off sum for its rights to the emtricitabine treatment, marketed as Emtriva, rather than continue collecting royalties throughout the drug's commercial life. James Wagner, president of Emory, said the agreement with Gilead Sciences and Royalty Pharma reflected a new trend towards universities cashing in on royalty rights to intellectual property rather than waiting for uncertain future returns.
The Financial Times